Sugar Maple Asset Management’s ADMA Biologics ADMA Stock Holding History

Sugar Maple Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$130K	Buy	+15,500	New	+$141K	0.08%	80

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sugar Maple Asset Management's ADMA Position: Q2 2026 in Review

Sugar Maple Asset Management opened a new position in ADMA Biologics (ADMA) in Q2 2026: 15,500 shares worth $130K. The stake represents 0.08% of the portfolio and ranks #80 among its holdings.

323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Sugar Maple Asset Management held 15,500 shares of ADMA Biologics worth $130K as of Q2 2026.
ADMA Biologics was a new Sugar Maple Asset Management position in Q2 2026.
ADMA Biologics made up 0.08% of Sugar Maple Asset Management's portfolio in Q2 2026, its #80 holding.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Sugar Maple Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.